Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cimetidine hydrochloride
Drug ID BADD_D00468
Description A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Indications and Usage For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.
Marketing Status Prescription; OTC; Discontinued
ATC Code A02BA01
DrugBank ID DB00501
KEGG ID D03503
MeSH ID D002927
PubChem ID 50963
TTD Drug ID D02DPA
NDC Product Code 0121-0649; 50383-966; 0121-1298; 49964-0019
Synonyms Cimetidine | N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine | Biomet | Biomet400 | Cimetidine Hydrochloride | Hydrochloride, Cimetidine | Cimetidine HCl | HCl, Cimetidine | Histodil | SK&F-92334 | SK&F 92334 | SK&F92334 | SKF-92334 | SKF 92334 | SKF92334 | Tagamet | Altramet | Eureceptor
Chemical Information
Molecular Formula C10H17ClN6S
CAS Registry Number 70059-30-2
SMILES CC1=C(N=CN1)CSCCNC(=NC)NC#N.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Haemolytic anaemiaUDP-glucuronosyltransferase 1A1P22309T93480Not Available
Haemolytic anaemiaL-lactate dehydrogenase B chainP07195Not AvailableNot Available
Hyperparathyroidism secondaryParathyroid hormoneP01270T98708Not Available
Hyperparathyroidism secondaryCalcineurin subunit B type 1P63098Not AvailableNot Available
ThrombocytopeniaBifunctional epoxide hydrolase 2P34913T35734Not Available
ThrombocytopeniaL-lactate dehydrogenase C chainP07864Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation19.06.02.001; 17.02.05.012--
Anxiety19.06.02.002--
Arthralgia15.01.02.001--
Arthropathy15.01.01.003--Not Available
Atrioventricular block02.03.01.002--Not Available
Blood creatinine increased13.13.01.004--
Bradycardia02.03.02.002--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Depression19.15.01.001--
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diarrhoea07.02.01.001--
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Erythema multiforme23.03.01.003; 10.01.03.015--
Gynaecomastia21.05.04.003; 05.05.02.003--
Hallucination19.10.02.002--
Headache17.14.01.001--
Hepatic fibrosis24.08.06.002; 09.01.04.002--Not Available
Hypersensitivity10.01.03.003--
Myalgia15.05.02.001--
Pancreatitis07.18.01.001--
Polymyositis15.05.01.004; 10.04.05.004--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Strongyloidiasis11.08.01.002; 07.19.02.006--Not Available
Tachycardia02.03.02.007--Not Available
Toxic epidermal necrolysis10.01.01.006; 23.03.01.008; 12.03.01.015; 11.07.01.006--
Urinary retention20.02.02.011--
The 1th Page    1 2    Next   Last    Total 2 Pages